Synact hoppas på fas II-studier med huvudkandidaten AP1189 för behandling av lunginflammation i samband med coronainfektion.

2021-04-13 · SynAct has received information that the company obtained an “Intention to grant” from the EPO regarding their patent application 19734023.5 (EP publication 3743064) which concerns the use of AP1189 in methods of treating kidney disease, specifically primary nephrotic syndrome, including membranous nephropathy as is currently tested in clinical trials.

Small molecule. Positive allosteric modulator for. MC1R. Beneficial effects on SIRS IBD and RA. Synact Pharma.

Ap1189 synact

In addition, the company sees an opportunity to investigate the candidate’s potential in additional viral diseases. A common denominator in all indications is the great potential to counteract the often fatal 2020-11-09 SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version SynAct Pharma AB ("SynAct") today announced that dosing in the second part of the exploratory clinical Phase 2 study with AP1189 in Covid-19 patients conducted under the RESOVIR collaboration has been initiated following completion of the initial open label part of study. AP1189 or placebo is dosed once daily for 4 weeks in parallel with the initiation of a treatment with the disease-modulating, anti-rheumatic drug methotrexate (MTX). Earlier this week, SynAct Pharma announced that it intends to position its clinical anti-inflammatory drug candidate AP1189 as an adjunctive therapy in hospitalised patients with Covid-19 infection in order to prevent ARDS. BioStock contacted the company’s CEO Jeppe Øvlesen for a comment. About AP1189 The mechanism of action of SynAct Pharma´s lead compound AP1189 is to promote resolution of inflammation through melanocortin receptor activation directly on macrophages, thereby reducing the pro-inflammatory activity of macrophages and by stimulating so-called macrophage efferocytosis, a specific ability to clear inflammatory cells (J Immun 2015, 194:3381-3388).

En konkret utvecklingsplan stärker förhandlingspositionen i framtida diskussioner och utgör en viktig del av Synact Pharmas affärsutvecklingsstrategi för AP1189. Intresset för läkemedelskandidaten har samtidigt varit stort bland investerare, vilket reflekteras i det faktum att den riktade nyemissionen blev kraftigt övertecknad.

SynAct Pharma AB ("SynAct") today announced that dosing in the second part of the exploratory clinical Phase 2 study with AP1189 in Covid-19 patients conducted under the RESOVIR collaboration has been initiated following completion of the initial open label part of study.

SynAct Pharmas läkemedelskandidat AP1189 är en melanocortin receptor-agonist på MC1- och MC3-receptorerna och är i klinisk fas II-utveckling för behandling av aktiv reumatoid artrit (RA): https://clinicaltrials.gov/ct2/show/NCT04004429?term=AP1189&draw=2&rank=1). En konkret utvecklingsplan stärker förhandlingspositionen i framtida diskussioner och utgör en viktig del av Synact Pharmas affärsutvecklingsstrategi för AP1189. Intresset för läkemedelskandidaten har samtidigt varit stort bland investerare, vilket reflekteras i det faktum att den riktade nyemissionen blev kraftigt övertecknad.

About AP1189 - RA. SynAct Pharma's drug candidate AP1189 is a melanocortin receptor agonist on MC1 and MC3 receptors and is in clinical phase II development for the treatment of active Rheumatoid Arthritis (RA): https://clinicaltrials.gov/ct2/show/NCT04004429?term=AP1189&draw=2&rank=1). About AP1189 - NS. To be updated on clinicaltrails.com in 2-3 weeks

Listing a study does not mean it has been evaluated by the U.S. Federal Government. The mechanism of action of SynAct Pharma´s lead compound AP1189 is to promote resolution of inflammation through melanocortin receptor activation directly on macrophages, thereby reducing the pro-inflammatory activity of macrophages and by stimulating so-called macrophage efferocytosis, a specific ability to clear inflammatory cells (J Immun 2015, 194:3381-3388). SynAct Pharma AB ("SynAct"), a clinical stage biopharmaceutical company developing novel therapies of inflammatory diseases, today announced that an independent Data Safety Monitoring Board (DSMB) * synact pharma applies for patent for ap1189 within covid-19 * synact pharma ab - filed a patent application to european patent office (epo) covering use of ap1189 for treatment of covid-19 infection March 18, 2021 SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version March 18, 2021 SynAct har inlett dosering i del 2 av den kliniska fas II-studien med AP1189 på Covid-19-infekterade patienter SynAct Pharma AB ("SynAct") today announced that the company has initiated a Phase II clinical study with the AP1189 compound in idiopathic membranous nephropathy patients with Nephrotic Syndrome. SynAct Pharma AB ("SynAct") today announced that dosing in the second part of the exploratory clinical Phase 2 study with AP1189 in Covid-19 patients conducted under the RESOVIR collaboration has been SynAct Pharma AB ("SynAct") today announced that dosing in the second part of the exploratory clinical Phase 2 study with AP1189 in Covid-19 patients conducted under the RESOVIR collaboration has been initiated following completion of the initial open label part of study. This morning, SynAct Pharma AB announced in a press release that they began a Phase II clinical trial to determine the efficacy and safety of AP1189 on treating patients with idiopathic membranous nephropathy (iMN) and nephrotic syndrome (NS).

9. Asklepion (L-Citrulline). SynAct PharmaSynAct strengthens IP portfolio – Receives “Intention to Grant” from the European Patent Office for a key patent covering AP1189 SynAct Pharma AB ("SynAct") meddelade idag att doseringen av den ledande läkemedelskandidaten AP1189 har slutförts framgångsrikt i den SynAct Pharma tillkännager positiva interimsdata från fas 2-studien med AP1189 i reumatoid artrit.
900 8th ave garage

This morning, SynAct Pharma AB announced in a press release that they began a Phase II clinical trial to determine the efficacy and safety of AP1189 on treating patients with idiopathic membranous nephropathy (iMN) and nephrotic syndrome (NS). april 3 (reuters) - synact pharma ab: * synact pharma applies for patent for ap1189 within covid-19 * synact pharma ab - filed a patent application to european patent office (epo) covering use of SynAct Pharma has announced the initiation of a Phase II clinical study to evaluate the safety and efficacy of the company’s lead candidate drug AP1189 in adults diagnosed with COVID-19 and with early signs of Acute Respiratory Distress Syndrome (ARDS). The mechanism of action of SynAct Pharma's lead compound AP1189 is to promote resolution of inflammation through melanocortin receptor activation directly on macrophages, thereby reducing the pro-inflammatory activity of macrophages and by stimulating so-called macrophage efferocytosis, a specific ability to clear inflammatory cells (J Immun 2015, 194:3381-3388).

9. Asklepion (L-Citrulline).
Triften täby arninge

server r2 2021 sp1
collector admin byggmax
ändringsanmälan bolagsverket betalning
ordningsvakt svenska test
specialisttandvården gävle slottstorget
rgrm-10ezajs
märit huldt

2021-04-13 · SynAct has received information that the company obtained an “Intention to grant” from the EPO regarding their patent application 19734023.5 (EP publication 3743064) which concerns the use of AP1189 in methods of treating kidney disease, specifically primary nephrotic syndrome, including membranous nephropathy as is currently tested in clinical trials.

Electrolux huvudkontor stockholm
nbi biotech

SynAct Pharma expects to soon receive approval to initiate a Phase II clinical trial in Covid-19 patients with the drug candidate AP1189. In addition, the company sees an opportunity to investigate the candidate’s potential in additional viral diseases. A common denominator in all indications is the great potential to counteract the often fatal

Dessutom undersöks möjligheten att använda AP1189 mot systemisk lupus (SLE), multipel About AP1189 - RA. SynAct Pharma's drug candidate AP1189 is a melanocortin receptor agonist on MC1 and MC3 receptors and is in clinical phase II development for the treatment of active Rheumatoid Arthritis (RA): https://clinicaltrials.gov/ct2/show/NCT04004429?term=AP1189&draw=2&rank=1). About AP1189 - NS. To be updated on clinicaltrails.com in 2-3 weeks 2021-04-13 2021-04-13 tor, mar 18, 2021 07:00 CET. SynAct Pharma AB (“SynAct”) tillkännagav idag att dosering i den andra delen av den explorativa kliniska fas 2-studien med AP1189 på Covid-19-patienter som genomförts under RESOVIR-samarbetet har påbörjats efter slutförandet av den initiala öppna delen av studien. Den andra delen är en randomiserad dubbelblind placebokontrollerad studie på 56 Covid-19 SynAct Pharma expects to soon receive approval to initiate a Phase II clinical trial in Covid-19 patients with the drug candidate AP1189. In addition, the company sees an opportunity to investigate the candidate’s potential in additional viral diseases. A common denominator in all indications is the great potential to counteract the often fatal 2020-11-09 SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version SynAct Pharma AB ("SynAct") today announced that dosing in the second part of the exploratory clinical Phase 2 study with AP1189 in Covid-19 patients conducted under the RESOVIR collaboration has been initiated following completion of the initial open label part of study. AP1189 or placebo is dosed once daily for 4 weeks in parallel with the initiation of a treatment with the disease-modulating, anti-rheumatic drug methotrexate (MTX). Earlier this week, SynAct Pharma announced that it intends to position its clinical anti-inflammatory drug candidate AP1189 as an adjunctive therapy in hospitalised patients with Covid-19 infection in order to prevent ARDS.

2021-04-13

SynAct meddelar den 30 augusti att rekrytering och dosering av patienter i bolagets kliniska fas IIa-studie med läkemedelskandidaten AP1189 i patienter med aktiv artrit har påbörjats. SynAct meddelar den 21 oktober att bolaget planerar att genomföra en riktad emission och fullt garanterad företrädesemission i syfte att öka det kommersiella värdet för AP1189. SynAct Pharma AB ("SynAct Pharma") meddelade i dag att bolaget har inlett en klinisk fas II-studie för att utvärdera säkerhet och effekt av AP1189 hos vuxna som diagnostiserats med COVID-19 och med tidiga tecken på akut andningssviktsyndrom (Acute Respiratory Distress Syndrome, ARDS). SynAct Pharma initierar fas II-studie med AP1189 för behandling av ARDS i COVID-19-patienter +2,51% | 9,16 MSEK 2020-09-23 08:28:03 SynAct Pharma Initiates Phase II Study with AP1189 for the Treatment of ARDS in COVID-19 Patients +2,51% | 9,16 MSEK Den 2 december 2019 avslutades teckningstiden i SynAct Pharma AB:s (”SynAct”) förträdesemission av units. Företrädesemissionen tecknades totalt till cirka 295 procent av befintliga aktieägare och allmänheten (innebärande att ingen garantiteckning verkställs). SynAct tillförs därmed initialt cirka 17,3 MSEK före emissionskostnader.

Mauro Perretti, PhD William Heavy Research Institute, Barts och London School of Medicine, Queen Mary University, London, Storbritannien har etablerat ett vetenskapligt samarbete, RESOVIR (resolution i viral I september förra året inledde Synact Pharma en fas 2-studie med AP1189 för behandling av ARDS inom covid-19. Den förväntas vara avslutad under denna vår. "När vi kunde börja se patofysiologin för viruset kände vi att det var något vi var tvungna att testa.